Literature DB >> 22831395

Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.

Samantha M Jaglowski1, Amy S Ruppert, Nyla A Heerema, Anissa Bingman, Joseph M Flynn, Michael R Grever, Jeffrey A Jones, Patrick Elder, Steven M Devine, John C Byrd, Leslie A Andritsos.   

Abstract

Complex karyotype (CK) on metaphase cytogenetics discriminates poor outcome in chronic lymphocytic leukaemia (CLL) patients undergoing salvage treatment; we hypothesized that it might provide prognostic information for patients undergoing allogeneic stem cell transplant. Fifty-one CLL patients were analysed following transplant; 18-month overall survival (OS), event-free survival (EFS) and cumulative incidence of progression estimates were 35%, 14% and 63%, respectively, in patients with CK (n = 19) versus 83%, 68% and 29% in patients without (n = 32) (P ≤ 0·0001, P ≤ 0·0001, and P = 0·02). In patients with high-risk interphase cytogenetics, CK remained predictive of worse OS (P = 0·02) and EFS (P = 0·009). These findings support further evaluation of metaphase karyotype in transplant risk assessment.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22831395      PMCID: PMC3719859          DOI: 10.1111/j.1365-2141.2012.09239.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.

Authors:  Matthias Ritgen; Alexandra Lange; Stephan Stilgenbauer; Hartmut Dohner; Christian Bretscher; Heidi Bosse; Ariane Stuhr; Michael Kneba; Peter Dreger
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

2.  Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.

Authors:  J A Woyach; G Lozanski; A S Ruppert; A Lozanski; K A Blum; J A Jones; J M Flynn; A J Johnson; M R Grever; N A Heerema; J C Byrd
Journal:  Leukemia       Date:  2012-01-13       Impact factor: 11.528

3.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

Authors:  John C Byrd; John G Gribben; Bercedis L Peterson; Michael R Grever; Gerard Lozanski; David M Lucas; Ben Lampson; Richard A Larson; Michael A Caligiuri; Nyla A Heerema
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

4.  Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

Authors:  Peter Dreger; Hartmut Döhner; Matthias Ritgen; Sebastian Böttcher; Raymonde Busch; Sascha Dietrich; Donald Bunjes; Sandra Cohen; Jörg Schubert; Ute Hegenbart; Dietrich Beelen; Matthias Zeis; Michael Stadler; Justin Hasenkamp; Lutz Uharek; Christof Scheid; Andreas Humpe; Thorsten Zenz; Dirk Winkler; Michael Hallek; Michael Kneba; Norbert Schmitz; Stephan Stilgenbauer
Journal:  Blood       Date:  2010-07-01       Impact factor: 22.113

5.  Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia.

Authors:  Carol Moreno; Neus Villamor; Dolors Colomer; Jordi Esteve; Rodrigo Martino; Josep Nomdedéu; Francesc Bosch; Armando López-Guillermo; Elías Campo; Jorge Sierra; Emili Montserrat
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

6.  Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.

Authors:  Mohamed L Sorror; Michael B Maris; Brenda M Sandmaier; Barry E Storer; Monic J Stuart; Ute Hegenbart; Edward Agura; Thomas R Chauncey; Jose Leis; Michael Pulsipher; Peter McSweeney; Jerald P Radich; Christopher Bredeson; Benedetto Bruno; Amelia Langston; Michael R Loken; Haifa Al-Ali; Karl G Blume; Rainer Storb; David G Maloney
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

7.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

8.  Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.

Authors:  Issa F Khouri; Ming-Sheng Lee; Rima M Saliba; Borje Andersson; Paolo Anderlini; Daniel Couriel; Chitra Hosing; Sergio Giralt; Martin Korbling; John McMannis; Michael J Keating; Richard E Champlin
Journal:  Exp Hematol       Date:  2004-01       Impact factor: 3.084

Review 9.  Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.

Authors:  P Dreger; R Brand; J Hansz; D Milligan; P Corradini; J Finke; G L Deliliers; R Martino; N Russell; A Van Biezen; M Michallet; D Niederwieser
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

10.  Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.

Authors:  Johannes Schetelig; Anja van Biezen; Ronald Brand; Dolores Caballero; Rodrigo Martino; Maija Itala; José A García-Marco; Liisa Volin; Norbert Schmitz; Rainer Schwerdtfeger; Arnold Ganser; Francesco Onida; Brigitte Mohr; Stephan Stilgenbauer; Martin Bornhäuser; Theo de Witte; Peter Dreger
Journal:  J Clin Oncol       Date:  2008-08-18       Impact factor: 44.544

View more
  14 in total

1.  Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.

Authors:  Philip A Thompson; Susan M O'Brien; William G Wierda; Alessandra Ferrajoli; Francesco Stingo; Susan C Smith; Jan A Burger; Zeev Estrov; Nitin Jain; Hagop M Kantarjian; Michael J Keating
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

2.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

3.  Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.

Authors:  Julio C Chavez; Mohamed A Kharfan-Dabaja; Jongphil Kim; Binglin Yue; Samir Dalia; Javier Pinilla-Ibarz; Claudio Anasetti; Frederick L Locke
Journal:  Leuk Res       Date:  2014-04-28       Impact factor: 3.156

4.  CpG Oligonucleotide and Interleukin 2 stimulation enables higher cytogenetic abnormality detection rates than 12-o-tetradecanolyphorbol-13-acetate in Asian patients with B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Fiona Pui San Liaw; Lai Ching Lau; Alvin Soon Tiong Lim; Tse Hui Lim; Geok Yee Lee; Sim Leng Tien
Journal:  Int J Hematol       Date:  2014-10-10       Impact factor: 2.490

Review 5.  Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Authors:  Peter Dreger; Johannes Schetelig; Niels Andersen; Paolo Corradini; Michel van Gelder; John Gribben; Eva Kimby; Mauricette Michallet; Carol Moreno; Stephan Stilgenbauer; Emili Montserrat
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

Review 6.  Prognostic Factors in the Era of Targeted Therapies in CLL.

Authors:  Prajwal Boddu; Alessandra Ferrajoli
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

7.  Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Authors:  Wael Saber; Jennifer R Brown; Haesook T Kim; Kwang Woo Ahn; Zhen-Huan Hu; Matthew S Davids; Virginia O Volpe; Joseph H Antin; Mohamed L Sorror; Mazyar Shadman; Oliver Press; Joseph Pidala; William Hogan; Robert Negrin; Steven Devine; Joseph Uberti; Edward Agura; Richard Nash; Jayesh Mehta; Joseph McGuirk; Stephen Forman; Amelia Langston; Sergio A Giralt; Miguel-Angel Perales; Minoo Battiwalla; Gregory A Hale; Robert Peter Gale; David I Marks; Mehdi Hamadani; Sid Ganguly; Ulrike Bacher; Hillard Lazarus; Ran Reshef; Gerhard C Hildebrandt; Yoshihiro Inamoto; Jean-Yves Cahn; Melhem Solh; Mohamed A Kharfan-Dabaja; Nilanjan Ghosh; Ayman Saad; Mahmoud Aljurf; Harry C Schouten; Brian T Hill; Attaphol Pawarode; Tamila Kindwall-Keller; Nakhle Saba; Edward A Copelan; Sunita Nathan; Amer Beitinjaneh; Bipin N Savani; Jan Cerny; Michael R Grunwald; Jean Yared; Baldeep M Wirk; Taiga Nishihori; Saurabh Chhabra; Richard F Olsson; Asad Bashey; Usama Gergis; Uday Popat; Ronald Sobecks; Edwin Alyea
Journal:  Clin Cancer Res       Date:  2019-06-28       Impact factor: 12.531

Review 8.  The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.

Authors:  Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas
Journal:  Diagnostics (Basel)       Date:  2021-05-10

Review 9.  Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go.

Authors:  Anna Puiggros; Gonzalo Blanco; Blanca Espinet
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

10.  Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions.

Authors:  Anna Puiggros; Rosa Collado; Maria José Calasanz; Margarita Ortega; Neus Ruiz-Xivillé; Alfredo Rivas-Delgado; Elisa Luño; Teresa González; Blanca Navarro; MaDolores García-Malo; Alberto Valiente; José Ángel Hernández; María Teresa Ardanaz; María Ángeles Piñan; María Laura Blanco; María Hernández-Sánchez; Ana Batlle-López; Rocío Salgado; Marta Salido; Ana Ferrer; Pau Abrisqueta; Eva Gimeno; Eugènia Abella; Christelle Ferrá; María José Terol; Francisco Ortuño; Dolors Costa; Carol Moreno; Félix Carbonell; Francesc Bosch; Julio Delgado; Blanca Espinet
Journal:  Oncotarget       Date:  2017-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.